Alchemy Biomedical Consulting -
 David Brown BSc, PhD, FRSC  
Dr David Brown has over 30 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche; and also as President and Chief Executive of Cellzome AG, a biotechnology company with headquarters in Heidelberg, Germany.  Whilst at Pfizer he was named co-inventor on the patent for Viagra, a treatment for male impotence, and he led the team that developed Viagra through to proof of clinical efficacy in human clinical trials.  He also had a pivotal role in the discovery of Relpax, a treatment for migraine. While at Roche in Switzerland, he was a Director of the company and had responsibility over 2000 staff focused on drug discovery at all six of Roche’s research sites in the USA, Europe and Asia. He also served on Clinical Development and Business Development senior committees.  
Since 2005 Dr Brown has pursued a portfolio of roles dedicated to bringing new medical treatments to both the developed and developing world. He provides consultancy services to the pharmaceutical, biotechnology and venture capital industries. He has been heavily involved with OneWorld Health, San Francisco, where his work, and that of the organization, is dedicated to bringing medicines to the poorest of the poor in the world. In particular he has been responsible for development of a global strategy to reduce child deaths from diarrheal diseases and other gastrointestinal disorders. This work has been funded by Bill Gates through his charitable trust, the Bill and Melinda Gates Foundation. In the developed world, his work focuses mostly on finding breakthrough treatments for bone disorders such as osteoarthritis, rheumatoid arthritis and associated pain, and also on neuropathic pain and acute and chronic nociceptive pain. He is an Honorary Fellow in Human Clinical Pain at Manchester University. 
Dr Brown has extensive experience of leadership at both Chief Executive and Board level. He is Chairman of Babraham Biotechnologies Ltd, which manages Babraham Research Campus, one of the large biotechnology parks surrounding Cambridge UK. He also currently serves on the boards of Amura Ltd (Chairman) and Crescendo Biologics. He is chairman of the Scientific Advisory Board of Heptares Ltd. He has previously served on the boards of Cellzome AG in Germany (as CEO) and the Institute for One World Health in San Francisco (as acting CEO then acting Chair of the Board). He is also co-founder and Chairman of a charity (FMVSO) supporting a school and orphanage for destitute children in India. He is based at Cambridge, UK.
Website provided by  Vistaprint
provided by Vistaprint